PetDx launches OncoK9™, a pioneering blood-based multi-cancer early detection (MCED) test for dogs
OncoK9 Initially Available at Select Petco Full-Service Veterinary Hospitals Beginning in May
SAN DIEGO, May 20, 2021 /PRNewswire/ — PetDx – The Liquid Biopsy Company for Pets™, a company dedicated to unleashing the power of genomics to improve pet health, announced today the launch of OncoK9™, a first-in-class multi-cancer early detection (MCED) test that enables veterinarians to achieve earlier detection of cancer in dogs with a simple blood draw.
Founded in 2019 in San Diego, PetDx develops noninvasive cancer testing solutions that incorporate many of the latest advances from the human liquid biopsy space and provide support to veterinarians at multiple decision points across the entire continuum of cancer care. The company’s first product, OncoK9, employs cutting-edge genomic analysis that leverages next-generation sequencing (NGS) technology and proprietary bioinformatics algorithms to offer new cancer-detection capabilities that empower veterinarians to provide superior care to canine patients. OncoK9 will be available to pets and their families at Petco’s full-service veterinary hospitals in select locations in May, and at veterinary clinics across the country starting in Summer 2021.
